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Supplementary appendix 
Supplementary table 1: Standardised dataset - data dictionary for the length of stay analyses 
Variable name in Stata Description 
 
Coding  
About the data 
study_group_id Study group identifier (lookup codes 
in MS Excel metadata file) 
Auto-numbering (_n); string 
patid Study specific patient ID as provided 
by study groups; this will only be 
retained in the individual datasets but 
dropped from the pooled dataset 
string  
auto_patid Auto-numbered patient ID generated 
for each study group dataset; this will 
only be retained in the individual 
datasets but dropped from the pooled 
dataset 
Auto-numbering (_n) 
pride_patid Unique patient identifier created by 
concatenation of study_group_id and 
auto-numbered patient id (auto_patid) 
string 
data_source Whether hospital, community or ICU 1=hospital 
2= ICU 
3= community 
country Country identifier string 
Patient characteristics 
age_years Age in years; continuous variable Place all under 1s in one category 
(replace <1s as ‘0’) 
sex gender 1=male 
0=female 
pregnant Pregnancy 
(for sub-group analyses including 
pregnant women, only women of 




(no separate code for ‘not 
applicable’; men and women not 
of child-bearing age will be 
dropped from any analyses 
including pregnant women) 
comorbidity Whether any co-existing comorbidity 
was present (either as recorded or 
derived on the basis of a record of one 
of the following comorbidities: 
asthma, COPD, other chronic lung 
disease, heart disease, cerebrovascular 
disease (not including uncomplicated 
hypertension), chronic  liver disease, 
chronic renal disease, diabetes, 
neurological disease (including 
neurodevelopmental disorders), 
lymphoma, leukaemia, other 
malignancy, immunosuppression) 
Note: pregnancy will not be 
considered a ‘comorbidity’ and nor 
will obesity 
1= any comorbidity 
0= no recorded comorbidity 
asthma Asthma as recorded 1= yes 
0= no 






COPD as recorded 1= yes 
0= no 
 
other_lung_ds Chronic pulmonary diseases (other 




heart_ds Chronic heart disease as recorded 
(includes congenital heart disease, 
hypertension with cardiac 
complications, chronic heart failure, 
individuals requiring regular 
medication and/or follow-up for 
ischaemic heart disease) 
1= yes 
0= no 
renal_ds Chronic kidney disease (CKD) as 
recorded including CKD at stage 3, 4 
or 5, chronic kidney failure, nephrotic 




liver_ds Chronic liver disease as recorded 




cerebrovascular_ds Cerebrovascular disease as recorded 
(including stroke, transient ischaemic 









diabetes Diabetes as recorded (including Type 
1 diabetes, type 2 diabetes requiring 
insulin or oral hypoglycaemic drugs, 
diet controlled diabetes.) 
1= yes 
0= no 
immunosuppression Immunosuppression due to disease or 
treatment. Includes patients 
undergoing chemotherapy leading to 
immunosuppression; asplenia or 
splenic dysfunction and HIV infection 




onset_date Date of onset of influenza like illness 
(ILI) 
Recorded as date dd/mm/yy 
admission_date Date of first admission to hospital 
(whether to a general ward, HDU or 
ICU) 
Recorded as date dd/mm/yy 
time_to_admission Time (in days) from onset of 
symptoms to hospital admission 
Recorded as number of days 
fever Fever on presentation (as recorded) 1= yes 
0= no 








flu_diag Method of diagnosis of swine flu 
whether clinical or laboratory 
diagnosis (this includes RT-PCR) 
1= clinical 
2= laboratory diagnosis (not 
otherwise specified) or RT-PCR 
confirmed 
Variable name in Stata Description 
 
Coding  




3= not recorded 
icu_transfer_cause Reason for transfer to ICU Free text 
treatment 
antiviral_start_date Date of start of antiviral treatment Recorded as dd/mm/yy 
preadmit_antiviral Preadmission antiviral (either 
oseltamivir, zanamivir or peramivir) 
1= yes 
0= no 
oseltamivir_start_date Date of start of oseltamivir treatment Recorded as dd/mm/yy 
preadmit_oseltamivir Preadmission oseltamivir 1= yes 
0= no 
zanamivir_start_date Date of start of zanamivir treatment Recorded as dd/mm/yy 
preadmit_zanamivir Preadmission zanamivir 1= yes 
0= no 
antibiotic_start_date Date of start of antibiotic treatment Recorded as dd/mm/yy 
preadmit_antibiotic Preadmission antibiotic 1= yes 
0= no 
hospital_oseltamivir Oseltamivir given in hospital 1= yes 
0= no 
hospital_zanamivir Zanamivir given in hospital 1= yes 
0= no 
hospital_peramivir Peramivir given in hospital 1=yes 
0=no 
hospital_antibiotic Antibiotics given in hospital 1= yes 
0= no 
antiviral_anytime Antiviral administered at any time 




early_antiviral1 Antiviral administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus no 
antiviral treatment 
1= early antiviral 
0= no antiviral 
early_antiviral2 Antiviral administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus late 
antiviral treatment 
1= early antiviral 
0= late antiviral 
lt_2days Antiviral administered >2 days of 
symptom onset (whether in the 
community or in hospital) versus no 
antiviral treatment 
1= late antiviral (>2 days) 
0= no treatment 
lt_5days Antiviral administered ≥5 days of 
symptom onset (whether in the 
community or in hospital) versus no 
antiviral treatment 
1= late antiviral (>5 days) 
0= no treatment 
oseltamivir_anytime Oseltamivir administered at any time 




early_oseltamivir1 Oseltamivir administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus no 
antiviral treatment  
1= early oseltamivir 
0= no antiviral treatment 
 
early_oseltamivir2 Oseltamivir administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus late 
oseltamivir (administered >2 days 
after symptom onset) 
1= early oseltamivir 
0= late oseltamivir 
Variable name in Stata Description 
 
Coding  
oseltamivir_dose Oseltamivir dose whether standard or 
not (standard dose being described as 
75 mg BD for 5 days in adults i.e. over 
13 years of age) 
1= standard 
0= non-standard dose 
zanamivir_anytime Zanamivir administered at any time 




early_zanamivir1 Zanamivir administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus no 
antiviral treatment  
1= early zanamivir 
0= no antiviral treatment 
 
early_zanamivir2 Zanamivir administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus late 
zanamivir (administered >2 days after 
symptom onset) 
1= early zanamivir 
0= late zanamivir 
peramivir_anytime Peramivir administered at any time 
(whether in the community or in 
hospital); note: peramivir was 
authorised for emergency use in 
patients with swine flu during the 
pandemic in some countries 
1= yes 
0= no 
early_peramivir1 Peramivir administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus no 
antiviral treatment  
1= early peramivir 
0= no antiviral treatment 
 
early_peramivir2 Peramivir administered ≤2 days of 
symptom onset (whether in the 
community or in hospital) versus late 
peramivir (administered >2 days after 
symptom onset) 
1= early peramivir 
0= late peramivir 






discharge_date Date of discharge from hospital Recorded as date dd/mm/yy 
length_of_stay Length of stay in hospital (whether 
general ward or ICU) in days 
Number of days 




icu_admit_care Date of admission to ICU Recorded as dd/mm/yy 
icu_discharge_date Date of ICU discharge Recorded as dd/mm/yy 
icu_lengthstay Length of ICU stay Recorded as a continuous 
variables (no. of days) 
pneumonia Pneumonia as recorded (whether 
clinically diagnosed or radiologically 
diagnosed or discerned from free text 
chest x-ray report findings ) 
1= yes 
0= no 
death Death (as recorded) 1= yes 
0= no 
dod Date of death Recorded as dd/mm/yy 
p Propensity scores for treatment- yes 
vs. no 
Recorded as a continuous 
variable between 0 and 1 
ps_quintile Propensity scores categorised into 
quintiles for each individual study for 
NAI treatment- yes vs. no 
Categorical variable with values 
from 1 to 5 (1=lowest quintile 
and 5=highest quintile) 
Variable name in Stata Description 
 
Coding  
p_1 Propensity scores for treatment- Early 
treatment (≤2days) vs. no NAI 
treatment 
Recorded as a continuous 
variable between 0 and 1 
ps1_quintile Propensity scores categorised into 
quintiles for each individual study for 
early treatment (≤2days) vs. no 
treatment 
Categorical variable with values 
from 1 to 5 (1=lowest quintile 
and 5=highest quintile) 
p_2 Propensity scores for treatment- Early 
treatment (≤2days) vs. Late treatment 
(>2 days) 
Recorded as a continuous 
variable between 0 and 1 
ps2_quintile Propensity scores categorised into 
quintiles for each individual study for 
early treatment (≤2days) vs. late 
treatment (>2 days) 
Categorical variable with values 
from 1 to 5 (1=lowest quintile 
and 5=highest quintile) 
p_lt2 Propensity scores for treatment- Late 
treatment (>2days) vs. no NAI 
treatment 
Recorded as a continuous 
variable between 0 and 1 
pslt2_quintile Propensity scores categorised into 
quintiles for each individual study for 
late treatment (>2days) vs. no NAI 
treatment 
Categorical variable with values 
from 1 to 5 (1=lowest quintile 
and 5=highest quintile) 
Supplementary table 2: Characteristics of individual studies contributing to the pooled analysis 

































1 Singapore ED; Single 
Centre 
110 110 24 (10 to 56) 62 (56.4) 2 (1 to 3) 110 (100) - 4 (3 to 5) 0 (0) 
2 Bangladesh Hospital; 
Surveillance 
147 121 22 (<1 to 72) 77 (63.7) 3 (2 to 5) 14 (11.6) 2 (14.3) 5 (3 to 6) - 
3 Spain ICU; Multi-
centre 
1091 812 46 (1 to 86) 487 (60.2) 4 (2 to 6) 803 (98.9) 192 (23.9) 16 (10 to 30) 812 (100) 
4 Mexico Outpatients, 
Hospitalised; 
Multi-centre 
446 237 39 (<1 to 81) 140 (59.1) - 237 (100) 73 (30.8) 15 (11 to 21) 48 (20.3) 




17 15 42 (19 to 63) 9 (60) 4 (3 to 7) 15 (100) 3 (20) 46 (26 to 61) 15 (100) 
6 Lithuania Hospital; Multi-
centre 
121 110 30.5 (18 to 83) 46 (41.8) 2 (1 to 3) 61 (55.5) 31 (52.5) 5 (3 to 8) 3 (2.8) 
7 Switzerland Outpatients, 
Hospitalised; 
Single Centre 
15 13 43 (30 to 74) 10 (79.9) 5 (1 to 6) 13 (100) 2 (15.4) 9 (8 to 13) 6 (46.2) 
8 Germany Hospital; Single 
Centre 
315 135 1.3 (<1 to 17.7) 78 (57.8) 2 (1 to 4) 39 (28.9) - 3 (2 to 5) 10 (7.7) 
9 China Outpatients, 
Hospitalised; 
Single Centre 
65 40 41 (14 to 75) 24 (60) 5 (3.5 to 6) 40 (100) 3 (7.5) 7 (5.5 to 11) 24 (60) 
10 China Hospital; Multi-
centre 
155 127 39 (15 to 84) 72 (56.7) 5 (3 to 7) 106 (83.5) 12 (12) 11 (5 to 19) 47 (37) 
11 Turkey ICU; Single 
Centre 
20 10 28.5 (15 to 72) 3 (30) 6 (3 to 7) 10 (100) 0 (0) 4.5 (3 to 8) 10 (100) 
12 Argentina Outpatients, 
Hospitalised; 
Single Centre 
36 17 37 (16 to 82) 9 (52.9) 3 (2 to 4) 17 (100) 7 (41.2) 6 (4 to 10) 3 (17.7) 
13 Spain Outpatients, 
Hospitalised; 
Multi-centre 
57 45 46 (18 to 84) 26 (57.8) 5 (3 to 7) 45 (100) 5 (11.1) 5 (3 to 8) 9 (20) 
14 Iran Outpatients, 
Hospitalised; 
Single Centre 
434 121 33 (14 to 86) 52 (43) 4.1 (2.1 to 6.1) 121 (100) 19 (18.5) 3 (2 to 5) 34 (28.1) 




148 30 5.2 (<1 to 18) 18 (60) 3 (1 to 5) 25 (83.3) - 4 (2 to 9) 6 (20) 
16 South Africa Hospital; Single 
Centre 
46 23 22 (<1 to 55.7) 1 (4.4) 1 (0 to 3.5) 23 (100) 10 (66.7) 15 (6 to 27) 11 (47.8) 
17 Argentina Hospital; Multi-
centre 
112 76 26.5 (<1 to 79) 14 (18.4) 2 (1 to 3) 75 (98.7) 40 (53.3) 5 (3 to 9.5) 19 (25) 
18 Poland Hospital; Single 
Centre 
24 18 6.5 (<1 to 16.5) 6 (33.3) - 18 (100) 13 (72.2) 4 (3 to 5) 1 (5.9) 
19 Jordan Hospital; Single 
Centre 
81 41 7 (1.1 to19) 25 (61) - 41 (100) 32 (84.2) 4 (3 to 6) 6 (14.6) 
20 Israel Outpatients, 
Hospitalised; 
Single Centre 
73 37 5.5 (1 to 16.9) 19 (51.4) - 25 (67.6) - 3 (2 to 6) 2 (5.4) 
21 Australia Hospital; Single 
Centre 
106 86 28 (1 to 76) 30 (34.9) - 75 (87.2) - 2 (1 to 4) 11 (12.8) 
22 Turkey Hospital; Single 
Centre 
204 200 30 (16 to 86) 95 (47.5) 3 (2 to 4) 192 (96) - 3 (2 to 5) 15 (7.5) 
23 Morocco Outpatients, 
Hospitalised; 
Single Centre 
640 16 29 (1 to 42) 6 (37.5) - 16 (100) - 4 (2.5 to 4) 2 (12.5) 
24 France Hospital; Single 
Centre 
1770 930 35 (<1 to 104) 476 (51.2) 2 (1 to 4) 855 (91.9) 364 (50.5) 5 (3 to 13) 671 (72.2) 
25 Spain Hospital; Multi-
centre 
698 656 41 (16 to 97) 346 (52.7) 3 (2 to 5) 627 (95.6) 213 (35.1) 6 (3 to 8) 87 (13.3) 
26 Singapore Outpatients, 
Hospitalised; 
Single Centre 
584 310 19.4 (<1 to 92.5) 160 (51.6) 2 (1 to 3) 258 (83.2) 84 (32.6) 2.5 (2 to 4) 21 (6.8) 
27 Canada Hospital; Multi-
centre 
300 260 5.2 (<1 to 18.7) 153 (58.9) 2 (1 to 4) 232 (89.2) 103 (44.6) 5 (3 to 10) 111 (42.7) 
28 Australia Hospital; Single 
Centre 
105 102 41.5 (15 to 79) 49 (48) 3 (2 to 6) 87 (85.3) 38 (43.4) 4.5 (3 to 8) 24 (23.5) 
29 Hong Kong Hospital; Single 
Centre 
69 56 46.5 (18 to 95) 22 (39.3) 2 (1 to 3) 51 (91.1) 22 (44.9) 4 (2 to 5.5) 1 (1.8) 
30 Argentina Hospital; Single 
Centre 
197 135 29 (<1 to 71) 67 (49.6) 4 (2 to 7) 135 (100) 37 (28.7) 5 (3 to 8) 24 (17.9) 




354 92 34 (<1 to 78) 49 (53.3) 3.5 (1 to 6) 66 (71.7) - 5 (3 to 8) 8 (8.7) 
32 Spain Hospital; Single 
Centre 
91 64 40.5 (13 to 78) 22 (34.4) 2 (0 to 3) 58 (90.6) 26 (44.8) 6 (4 to 16) 18 (28.1) 
33 UK Hospital; 
Surveillance 
272 169 27 (16 to 44) 0 (0) 2 (1 to 4) 140 (82.8) 59 (47.2) 3 (2 to 6) 33 (19.5) 
34 Italy Hospital; Single 
Centre 
81 78 31 (1 to 81) 43 (55.1) - 66 (84.6) 50 (75.8) 5 (3 to 7) 7 (9) 
35 Turkey Hospital; Single 
Centre 
15 13 2.2 (<1 to 6) 6 (46.2) 0 (0 to 1) 13 (100) 12 (92.3) 1 (1 to 2) 2 (15.4) 
36 Israel Hospital; Multi-
centre 
506 480 42 (16 to 89) 229 (47.7) 3 (1 to 4) 426 (88.8) 174 (40.9) 6 (4 to 9) 21 (4.4) 
37 Brazil Hospital; Single 
Centre 
21 20 23.5 (15to 32) 0 (0) 1 (0 to 2) 20 (100) 15 (83.3) 5.5 (3 to 13) 5 (26.3) 
38 France Outpatients, 
Hospitalised; 
Single Centre 
139 72 25 (16 to 42) 0 (0) 2 (1 to 2) 62 (86.1) 52 (83.9) 4 (3 to 4) 1 (1.4) 
39 Greece Hospital; Single 
Centre 
34 34 33.5 (14 to 65) 23 (67.7) - 34 (100) 34 (100) 6 (5 to 6) 0 (0) 
40 Brazil ICU; Multi-
centre 
37 16 36 (18 to 80) 9 (56.3) 7.5 (4 to 10) 15 (93.8) - 10.5 (6.5 to 29) 16 (100) 
41 Finland ICU; Multi-
centre 
132 104 45.5 (<1 to 77) 68 (65.4) 3 (1 to 6) 99 (95.2) 39 (40.6) 14 (7 to 25) 104 (100) 
42 Egypt Hospital; 
Surveillance 
1943 822 21 (<1 to 77) 471 (57.3) 1 (1 to 3) 822 (100) 547 (72.1) 6 (5 to 8) - 
43 USA Hospital; Single 
Centre 
307 263 5.8 (<1 to 21.6) 155 (58.9) 3 (1 to 5) 230 (87.5) 96 (42.1) 3 (3 to 6) 66 (25.1) 
44 Turkey Hospital; 
Surveillance 
114 102 6.3 (<1 to 15.6) 62 (60.8) 2 (2 to 4) 102 (100) 52 (51) 6 (5 to 10) 12 (11.8) 
45 Canada Hospital; Single 
Centre 
81 65 1.1 (<1 to 15) 34 (52.3) 4 (2 to 7) 40 (61.5) 4 (10.3) 4 (2 to 6) 8 (12.3) 
46 Denmark ICU; 
Surveillance 
53 21 41.1 (5.8 to 63.1) 12 (57.1) 4.5 (1 to 7) 21 (100) 6 (30) 12 (3 to 24) 21 (100) 
47 Saudi Arabia Hospital; Single 
Centre 
127 121 27 (10.9 to 79) 97 (80.2) 2.5 (1 to 4) 121 (100) 59 (49.2) 6 (5 to 9) 10 (8.3) 
48 Slovenia Outpatients, 
Hospitalised; 
Single Centre 
78 40 23.6 (<1 to 87.1) 29 (72.5) 2 (1 to 5) 25 (62.5) 6 (27.3) 4 (2 to 6) 3 (7.5) 
49 Japan Hospital; Single 
Centre 
104 102 7 (<1 to 71) 53 (52) 2 (1 to 3) 102 (100) 76 (74.5) 7 (5 to 9) 4 (3.9) 
50 India Hospital; Single 
Centre 
61 51 20 (<1 to 52) 31 (60.8) 5 (3 to 7) 51 (100) 7 (13.7) 7 (6 to 11) 2 (3.9) 
51 Mexico Outpatients, 
Hospitalised; 
Surveillance 
127289 5,034 28 (<1 to 99) 2,192 
(43.5) 
2 (1 to 5) 927 (18.4) - 4 (2 to 7) 189 (3.8) 
52 China Hospital; Single 
Centre 
72 19 43 (18 to 62) 12 (63.2) 8 (5 to 10) 19 (100) 0 (0) 11 (8 to 22) 8 (42.1) 
53 Croatia Hospital; Single 
Centre 
169 160 29 (<1 to 83) 90 (56.3) 2 (1 to 4) 131 (81.9) 69 (52.7) 6 (4 to 10) 28 (17.5) 
54 UK Hospital; Multi-
centre 
1520 1,163 26 (<1 to 95) 541 (46.5) 2 (1 to 4) 879 (75.6) 265 (46.3) 4 (2 to 6) 158 (13.6) 
55 Poland Hospital; Single 
Centre 
13 8 18.5 (6 to 75) 3 (37.5) 2 (1 to 2) 6 (75) 2 (50) 9.5 (5.5 to 11.5) 1 (12.5) 
56 Slovenia Hospital; Single 
Centre 
66 60 38.5 (16.6 to 
87.2) 
29 (48.3) 4 (2 to 6) 58 (96.7) 14 (26.9) 4 (3 to 6) 6 (10) 
57 Serbia Hospital; Single 
Centre 
98 95 27 (14 to 88) 66 (69.5) 2 (1 to 5) 67 (70.5) 31 (46.3) 7 (6 to 8) 4 (4.2) 
58 UK ICU; Single 
Centre 
24 17 50 (22 to 80) 10 (58.8) 6 (3 to 8) 17 (100) 1 (5.9) 32 (14 to 47) 17 (100) 
59 Argentina Hospital; Multi-
centre 
251 191 0.8 (<1 to 17.7) 98 (51.3) 4 (2 to 7) 156 (81.7) 16 (10.3) 8 (5 to 13) 28 (14.7) 
60 China Hospital; Multi-
centre 
367 321 20 (<1 to 77) 184 (57.3) 2 (1 to 4) 318 (99.1) 94 (51.1) 7 (5 to 9) 35 (10.9) 
61 Austria Outpatients, 
Hospitalised; 
Multi-centre 
540 325 20.3 (<1 to 90.8) 230 (70.8) - 230 (70.8) - 7 (4 to 9) 34 (10.5) 
62 Iran Hospital; Multi-
centre 
484 433 31 (1 to 84) 181 (41.8) 3 (2 to 7) 420 (97) 113 (28.1) 3 (1 to 4) 37 (8.6) 
63 Mongolia Hospital; 
Surveillance 
204 180 20 (1 to 76) 89 (49.4) 3 (1 to 5) 96 (53.3) - 5 (4 to 7) 6 (3.3) 
64 Germany Hospital; Single 
Centre 
92 89 3.6 (<1 to 17.8) 45 (50.6) 2 (1 to 4) 26 (29.2) 18 (69.2) 3 (2 to 5) 6 (6.7) 
65 Australia Hospital; Single 
Centre 
601 433 3.5 (<1 to 14.9) 252 (58.2) 2 (1 to 4) 221 (51) 101 (49.5) 2 (1 to 5) 48 (11.1) 
66 Bangladesh Hospital; Single 
Centre 
28 8 23 (3 to 50) 2 (25) 1 (0 to 4) 8 (100) 4 (57.1) 5.5 (4 to 6) - 
67.1 USA Hospital; Multi-
centre 
630 432 47 (13 to 92) 184 (42.6) 3 (2 to 6) 401 (92.8) 1 (16.7) 11 (5.5 to 22) 432 (100) 
67.2 USA Hospital; Multi-
centre 
838 699 6 (<1 to 20) 412 (58.9) 2 (1 to 4) 628 (89.8) 3 (75) 7 (4 to 15) 699 (100) 
68 UK Hospital; Single 
Centre 
41 20 2 (<1 to 14.4) 9 (45) 3.5 (0.5 to 5) 16 (80) 5 (31.3) 5 (3 to 18.5) 7 (35) 
69 Canada Hospital; Single 
Centre 
1014 899 27 (<1 to 92) 460 (51.2) 3 (2 to 5) 656 (73) 293 (44.7) 3 (2 to 6) 119 (13.2) 
70 Norway Hospital; Single 
Centre 
129 105 43.6 (15.1 to 
93.2) 
50 (47.6) 4 (1 to 7) 75 (71.4) 29 (38.7) 3 (2 to 6) 7 (6.7) 
Percentages based on available data 
ED- Emergency department; ICU- Intensive care unit; NAI- Neuraminidase inhibitor; IQR- Interquartile range 
  
Supplementary table 3: Impact of in-hospital NAI treatment on hospital length of stay in pregnant women and 
patients with obesity 
RR: Rate Ratio; 95%CI: 95% Confidence Interval (bold font indicates statistical significance at the 5% level (p<0.05); a) 
RR adjusted for propensity scores (quintiles) for receiving treatment, antibiotic treatment received in hospital, steroid 




RR (95% CI) 
Adjusteda 
RR (95% CI) 
NAI anytime vs No NAI treatment 1.10 (0.95 to 1.27) 1.03 (0.89 to 1.19) 
Early NAI treatment vs Later NAI treatment 0.56 (0.48 to 0.65) 0.61 (0.52 to 0.70) 
Early NAI treatment vs No NAI treatment 0.98 (0.80 to 1.19) 0.90 (0.74 to 1.10) 
NAI treatment on the day of hospital admission vs No NAI 
treatmentb 
1.18 (0.96 to 1.16) 1.05 (0.85 to 1.29) 
NAI treatment on the day of hospital admission vs Later/No 
NAI treatmentb 
0.80 (0.69 to 0.93) 0.75 (0.64 to 0.88) 
Obesity (n=1,677)   
NAI anytime vs No NAI treatment 1.21 (1.06 to 1.39) 1.14 (0.99 to 1.31) 
Early NAI treatment vs Later NAI treatment 0.67 (0.59 to 0.76) 0.73 (0.65 to 0.83) 
Early NAI treatment vs No NAI treatment 1.09 (0.88 to 1.34) 0.95 (0.74 to 1.21) 
NAI treatment on the day of hospital admission vs No NAI 
treatmentb 
1.10 (0.86 to 1.41) 1.13 (0.86 to 1.48) 
NAI treatment on the day of hospital admission vs Later/No 
NAI treatmentb 0.79 (0.68 to 0.91) 0.80 (0.69 to 0.93) 
Supplementary figure 1: Histogram showing the distribution of hospital length of stay for our study population  
(a) distribution of length of stay from 0 to 30 days (b) distribution of length of stay >30 days 
 
Supplementary table 4: PRIDE study Investigators 
Authors Author Affiliation  
YS Leo, WM Kyaw  Department of Infectious Diseases,  Tan Tock Seng 
Hospital, Singapore 
A Al Mamun 1, M Rahman 2,  E Azziz-
Baumgartner 3 
1 British Columbia Centre for Disease Control, 
Vancouver, British Columbia, Canada  
2 Institute of Epidemiology, Disease Control and 
Research (IEDCR), Dhaka, Bangladesh 
3 Influenza Division, National Center for 
Immunization and Respiratory Diseases, Centers 
for Disease Control and Prevention, Atlanta, 
Georgia, USA 
A H Rodríguez* for the H1N1 Sociedad 
Española de Medicina Intensiva, Crítica y 
Unidades Coronarias (SEMICYUC) working 
group 
*Hospital Joan XXIII, Critical Care Department - 
IISPV - URV - CIBERES, Tarragona, Spain 
E Bautista 1, AL Higuera Iglesias 2 1 Critical Care Department, Instituto Nacional de 
Enfermedades Respiratorias, Ismael Cosío 
Villegas, Mexico City, Mexico 
2 Epidemiology Research Unit, Instituto Nacional 
de Enfermedades Respiratorias, Ismael Cosío 
Villegas, Mexico City, Mexico 
A Mickiene, D Velyvyte Lithuanian University of Health Sciences, Kaunas, 
Lithuania 
B Bertisch1, M Hoffmann2 1 Institute of Global Health, University of Geneva 
2Division of Infectious Diseases and Hospital 
Epidemiology, Kantonsspital St. Gallen, 
Switzerland 
B A Rath1, B Schweiger2 1 Department of Pediatrics, Division of 
Pneumonology-Immunology, Charité University 
Medical Center, Berlin, Germany 
2 National Reference Centre Influenza at Robert 
Koch Institute, Berlin, Germany 
B Cao, X Li Beijing Chao-Yang Hospital, Capital Medical 
University, Beijing, China 
B Du, X Hu  Peking Union Medical College Hospital, Beijing, 
China 
B Sertogullarindan, B Ozbay Yuzuncu Yil University Medical Faculty, 
Department of Pulmonary Medicine Van, Turkey 
C Bantar, ME Oliva Dept. of Infection Control, Hospital San Martín de 
Paraná,  Entre Ríos, Argentina 
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